Clinical trials used doses as high as 1 mg per day without safety concerns, but 300 mcg is the most commonly referenced dose in peptide medicine literature and in the investigational protocols that have been published since the formal trials concluded
They show that GLP-1R agonists can reduce amyloidosis and mitigate Alzheimers disease symptoms in mice by activating AMPK signaling, regulating neuronal amyloid- metabolism and promoting microglial phagocytosis
In a meta-analysis with six studies (three liraglutide studies, three exenatide studies), treatment of GLP-1RAs produced significant improvements in liver histology such as lobular inflammation, hepatocellular ballooning, and fibrosis [78]
The team then tracked each groups eyes over the following 12 months
If you are starting fresh, the question of which drug to start on is now genuinely fragmented and worth a real conversation with a clinician who is current on the comparative landscape